CG Oncology (CGON) Expected to Announce Quarterly Earnings on Tuesday

CG Oncology (NASDAQ:CGON) is anticipated to announce its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $0.11 million for the quarter.

CG Oncology Stock Performance

CG Oncology stock opened at $27.67 on Tuesday. CG Oncology has a 12-month low of $23.91 and a 12-month high of $46.99. The company has a 50-day moving average price of $28.32 and a 200 day moving average price of $32.40.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. TD Cowen assumed coverage on shares of CG Oncology in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Royal Bank of Canada restated an “outperform” rating and set a $66.00 price objective on shares of CG Oncology in a research report on Friday, December 6th. Morgan Stanley restated an “overweight” rating and set a $55.00 price objective on shares of CG Oncology in a research report on Friday, March 7th. Finally, HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a research report on Friday, January 10th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $63.88.

Insider Buying and Selling at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.